The earnings call highlighted significant progress in Dyadic's transition towards commercializing non-pharmaceutical products and securing strategic partnerships with milestone payments. However, the call also reflected concerns over reduced collaborations and a decrease in cash reserves, alongside a consistent net loss. The focus on non-pharmaceutical commercialization and milestone achievements suggests a promising outlook despite the financial challenges.

Company Guidance -

Q2 2025

During the Dyadic International First Quarter 2025 Financial Results Conference Call, the guidance provided highlighted strategic shifts and upcoming initiatives aimed at driving revenue growth. The company emphasized its focus on commercializing non-pharmaceutical products across life sciences, bioactives, ingredients, and industrial sectors, leveraging its proprietary C1 and Dapibus microbial expression platforms. Dyadic anticipates launching recombinant human serum albumin in Q3 2025, targeting a $6.1 billion cell culture media market, and expects a third milestone payment in Q2 related to productivity improvements. The company is also advancing recombinant transferrin and fibroblast growth factors, with plans for Q2 sampling. In DNA/RNA tools, Dyadic is progressing with DNase1 and other enzyme prototypes targeting a $4 billion market by 2028. Furthermore, developments in animal-free dairy proteins, with a market value of $26.5 billion in 2023, include alpha-lactalbumin and human lactoferrin, with sampling efforts anticipated in late 2025. In industrial applications, Dyadic's EN3ZYME, launched in 2024, received a large follow-on order in Q1 2025. Financially, Dyadic reported Q1 2025 revenue of approximately $394,000, a net loss of $2,028,000, and cash reserves of $7.4 million as of March 31, 2025, as the company aims to support near-term revenue growth and strategic objectives.

Increase in Total Revenue

Total revenue for the quarter ended March 31, 2025 increased to approximately $394,000 compared to $335,000 for the same period 1 year ago.

Major Collaboration and Grant Achievements

Dyadic secured a $4.5 million grant from CEPI and a $3 million program funded by the Gates Foundation, contributing to non-dilutive funding for vaccine and antibody development.

Commercialization of Non-Pharmaceutical Products

Focus on commercial-ready non-pharmaceutical products, including the expected launch of recombinant human serum albumin in Q3 2025 and ongoing development of other enzyme products.

Strategic Partnerships and Milestone Payments

Anticipation of achieving a third milestone payment related to productivity improvements in Q2 2025.

Cost Reduction

G&A expenses decreased by 10.8% to $1,596,000 compared to $1,789,000 for the same period a year ago.

Progress in Industrial Applications

Significant progress with enzyme systems that enhance process efficiency, including a large follow-on purchase order for EN3ZYME from Fermbox Bio.

Dyadic International (DYAI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DYAI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.06 / -	-0.07	―	―	―
May 14, 2025	2025 (Q1)	- / -0.07	-0.07	0.00% (0.00)	―
Mar 26, 2025	2024 (Q4)	-0.04 / -0.05	-0.08	37.50% (+0.03)	―
Nov 12, 2024	2024 (Q3)	-0.07 / -0.01	-0.06	83.33% (+0.05)	―
Aug 13, 2024	2024 (Q2)	-0.07 / -0.07	-0.07	0.00% (0.00)	―
May 14, 2024	2024 (Q1)	- / -0.07	-0.03	-133.33% (-0.04)	―
Mar 28, 2024	2023 (Q4)	-0.07 / -0.08	-0.07	-14.29% (>-0.01)	―
Nov 08, 2023	2023 (Q3)	-0.06 / -0.06	-0.06	0.00% (0.00)	―
Aug 09, 2023	2023 (Q2)	-0.05 / -0.07	-0.12	41.67% (+0.05)	―
May 10, 2023	2023 (Q1)	- / -0.03	-0.09	66.67% (+0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DYAI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$1.04	$1.00	-3.85%
Mar 26, 2025	$1.33	$1.35	+1.50%
Nov 12, 2024	$1.14	$1.12	-1.75%
Aug 13, 2024	$1.35	$1.36	+0.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dyadic International Inc. (DYAI) report earnings?

Dyadic International Inc. (DYAI) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is Dyadic International Inc. (DYAI) earnings time?

Dyadic International Inc. (DYAI) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DYAI EPS forecast?

DYAI EPS forecast for the fiscal quarter 2025 (Q2) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing